AC Immune Announces Positive Interim Data From Early Parkinson's Disease Study

(RTTNews) - AC Immune SA (ACIU), Wednesday announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056 for the treatment of patients with early Parkinson's disease.

Part 1 of the adaptive, placebo-controlled, and biomarker-based Phase 2 study involved over 30 patients, who were randomly assigned to receive ACI-7104.056 or placebo at a ratio of 3:1.

The interim results showed that positive antibody responses were effectively induced against the target antigen at week 6 after 2 immunizations and were further boosted by each additional immunization.

Additionally, the findings revealed an increase in anti-a-syn antibodies on average over 20-fold higher than the placebo background level after four immunizations.

Dr. Andrea Pfeifer, CEO of the company stated that, "These additional interim safety and immunogenicity data after 6 months of treatment underscore the good safety profile and reinforce the best-in-class characteristics of ACI-7104.056 for the treatment of Parkinson's disease. We look forward to sharing further updates later in 2025."

The company might decide to initiate Part 2 of VacSYn with up to 150 patients based on this interim data along with pharmacodynamic and biomarker data.

The exploratory endpoints for patients in Part 2 will include the evaluation of the progression of motor and non-motor symptoms of the disease, as well as digital, imaging, and fluid biomarkers.

On Tuesday, AC's stock closed at $1.79, down 4.01 percent on the Nasdaq.